XLOXilio Therapeutics, Inc.
- Market cap
- $49.81M
- as of 2026-10-23
- Latest close
- $7.57
- as of 2026-10-23
- Sector
- Healthcare
- as of 2026-10-24
- Industry
- Biotechnology
- as of 2026-10-24
Cluster
No cluster in the last 90 days under the default rule (14d · ≥2 insiders · all roles).
Form 4 historysince 2024-01-03
| Insider | Traded | Filed | Type | Shares | Price | Value | Owned after | 10b5-1 plan | Filing |
|---|---|---|---|---|---|---|---|---|---|
| Houvras YarivCHIEF MEDICAL OFFICER | Oct 1 | Oct 2 | A · derivative | 105,000 | $8.91 | $935,550 | 105,000 | No | Form 4 |
| Brennan Aoife | Jun 11 | Jun 12 | A · derivative | 5,000 | $7.99 | $39,950 | 5,000 | No | Form 4 |
| Bonstein Sara | Jun 11 | Jun 12 | A · derivative | 5,000 | $7.99 | $39,950 | 5,000 | No | Form 4 |
| Ross Robert W. | Jun 11 | Jun 12 | A · derivative | 5,000 | $7.99 | $39,950 | 5,000 | No | Form 4 |
| Xu Yuan | Jun 11 | Jun 12 | A · derivative | 5,000 | $7.99 | $39,950 | 5,000 | No | Form 4 |
| Bello Akintunde Olatokumbo | Jun 11 | Jun 12 | A · derivative | 5,000 | $7.99 | $39,950 | 5,000 | No | Form 4 |
| Shannon James Samuel | Jun 11 | Jun 12 | A · derivative | 5,000 | $7.99 | $39,950 | 5,000 | No | Form 4 |
| Curran Daniel J. | Jun 11 | Jun 12 | A · derivative | 5,000 | $7.99 | $39,950 | 5,000 | No | Form 4 |
| Blanchard Cheryl R | Apr 15 | Apr 16 | A · derivative | 10,000 | $8.40 | $84,000 | 10,000 | No | Form 4 |
| Shannon James Samuel | Mar 26 | Mar 30 | P | 5,000 | $8.79 | Purchase +$43,950 | 10,000 | No | Form 4 |
| Gilead Sciences, Inc. | Feb 13 | Feb 17 | P · derivative | 3,739,000 | $0.53 | Purchase +$1,981,670 | 40,384,266 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Jan 2 | Jan 5 | S | 7,030 | $0.64 | Sale −$4,499 | 24,766 | Yes | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Jan 2 | Jan 5 | S | 1,826 | $0.64 | Sale −$1,169 | 6,371 | Yes | Form 4 |
| Russo RenePRESIDENT AND CEO | Jan 1 | Jan 5 | M | 44,250 | not reported | not reported | 325,422 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Jan 1 | Jan 5 | M · derivative | 44,250 | $0.00 | $0 | 88,500 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Jan 1 | Jan 5 | M | 19,375 | not reported | not reported | 31,796 | Yes | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Jan 1 | Jan 5 | M · derivative | 19,375 | $0.00 | $0 | 38,750 | Yes | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Jan 1 | Jan 5 | M | 5,000 | not reported | not reported | 8,197 | Yes | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Jan 1 | Jan 5 | M · derivative | 5,000 | $0.00 | $0 | 10,000 | Yes | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Jan 1 | Jan 5 | M | 16,625 | not reported | not reported | 33,250 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Jan 1 | Jan 5 | M · derivative | 16,625 | $0.00 | $0 | 33,250 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Dec 31, 2025 | Jan 5 | A · derivative | 1,500,258 | $0.84 | $1,260,217 | 1,500,258 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Dec 31, 2025 | Jan 5 | A · derivative | 668,789 | $0.84 | $561,783 | 668,789 | Yes | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Dec 31, 2025 | Jan 5 | A · derivative | 95,221 | $0.84 | $79,986 | 95,221 | Yes | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Dec 31, 2025 | Jan 5 | A · derivative | 451,885 | $0.84 | $379,583 | 451,885 | No | Form 4 |
| Gilead Sciences, Inc. | Nov 26, 2025 | Dec 1, 2025 | X · derivative | 13,335,000 | $0.75 | $10,001,250 | 36,645,266 | No | Form 4 |
| Gilead Sciences, Inc. | Nov 26, 2025 | Dec 1, 2025 | X · derivative | 13,335,000 | $0.75 | $10,001,250 | not reported | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 2,075,000 | $0.84 | $1,743,000 | 2,075,000 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 239,703 | $5.51 | $1,320,764 | not reported | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 239,703 | $1.50 | $359,555 | 239,703 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 473,334 | $5.89 | $2,787,937 | not reported | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 473,334 | $1.50 | $710,001 | 473,334 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 135,134 | $11.69 | $1,579,716 | not reported | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 135,134 | $1.50 | $202,701 | 135,134 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 50,041 | $16.00 | $800,656 | not reported | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 50,041 | $1.50 | $75,062 | 50,041 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 100,000 | $13.83 | $1,383,000 | not reported | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 100,000 | $1.50 | $150,000 | 100,000 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 150,000 | $12.66 | $1,899,000 | not reported | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 150,000 | $1.50 | $225,000 | 150,000 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 350,000 | $2.69 | $941,500 | not reported | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 350,000 | $1.50 | $525,000 | 350,000 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 700,000 | $2.79 | $1,953,000 | not reported | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 700,000 | $1.50 | $1,050,000 | 700,000 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 925,000 | $0.84 | $777,000 | 925,000 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 155,090 | $6.65 | $1,031,349 | not reported | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 155,090 | $1.50 | $232,635 | 155,090 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 23,786 | $6.65 | $158,177 | not reported | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 23,786 | $1.50 | $35,679 | 23,786 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 37,296 | $16.00 | $596,736 | not reported | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 37,296 | $1.50 | $55,944 | 37,296 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 45,000 | $12.66 | $569,700 | not reported | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 45,000 | $1.50 | $67,500 | 45,000 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 20,000 | $2.13 | $42,600 | not reported | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 20,000 | $1.50 | $30,000 | 20,000 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 117,000 | $2.69 | $314,730 | not reported | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 117,000 | $1.50 | $175,500 | 117,000 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 150,000 | $2.75 | $412,500 | not reported | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 150,000 | $1.50 | $225,000 | 150,000 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 300,000 | $2.79 | $837,000 | not reported | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 300,000 | $1.50 | $450,000 | 300,000 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 625,000 | $0.84 | $525,000 | 625,000 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 44,210 | $9.69 | $428,395 | not reported | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 44,210 | $1.50 | $66,315 | 44,210 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 15,000 | $2.37 | $35,550 | not reported | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 15,000 | $1.50 | $22,500 | 15,000 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 35,000 | $2.69 | $94,150 | not reported | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 35,000 | $1.50 | $52,500 | 35,000 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 25,000 | $2.79 | $69,750 | not reported | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 25,000 | $1.50 | $37,500 | 25,000 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 106,000 | $2.79 | $295,740 | not reported | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 106,000 | $1.50 | $159,000 | 106,000 | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 131,700 | $0.84 | $110,628 | 131,700 | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 55,000 | $3.17 | $174,350 | not reported | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 55,000 | $1.00 | $55,000 | 55,000 | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 25,000 | $2.79 | $69,750 | not reported | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 25,000 | $1.00 | $25,000 | 25,000 | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | Nov 25, 2025 | D · derivative | 20,000 | $1.08 | $21,600 | not reported | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Nov 21, 2025 | Nov 25, 2025 | A · derivative | 20,000 | $1.00 | $20,000 | 20,000 | No | Form 4 |
| Shannon James Samuel | Jun 17, 2025 | Jun 18, 2025 | P | 25,000 | $0.69 | Purchase +$17,250 | 70,000 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Jun 16, 2025 | Jun 18, 2025 | P | 36,289 | $0.68 | Purchase +$24,677 | 281,172 | No | Form 4 |
| Shannon James Samuel | Jun 16, 2025 | Jun 18, 2025 | P | 45,000 | $0.69 | Purchase +$31,050 | 45,000 | No | Form 4 |
| Rossi Christina | Jun 11, 2025 | Jun 12, 2025 | A · derivative | 31,000 | $0.69 | $21,390 | 31,000 | No | Form 4 |
| Shannon James Samuel | Jun 11, 2025 | Jun 12, 2025 | A · derivative | 31,000 | $0.69 | $21,390 | 31,000 | No | Form 4 |
| Xu Yuan | Jun 11, 2025 | Jun 12, 2025 | A · derivative | 31,000 | $0.69 | $21,390 | 31,000 | No | Form 4 |
| Clancy Paul J | Jun 11, 2025 | Jun 12, 2025 | A · derivative | 31,000 | $0.69 | $21,390 | 31,000 | No | Form 4 |
| Curran Daniel J. | Jun 11, 2025 | Jun 12, 2025 | A · derivative | 31,000 | $0.69 | $21,390 | 31,000 | No | Form 4 |
| Bonstein Sara | Jun 11, 2025 | Jun 12, 2025 | A · derivative | 31,000 | $0.69 | $21,390 | 31,000 | No | Form 4 |
| Brennan Aoife | Jun 11, 2025 | Jun 12, 2025 | A · derivative | 31,000 | $0.69 | $21,390 | 31,000 | No | Form 4 |
| Ross Robert W. | Jun 11, 2025 | Jun 12, 2025 | A · derivative | 31,000 | $0.69 | $21,390 | 31,000 | No | Form 4 |
| Bello Akintunde Olatokumbo | Jun 10, 2025 | Jun 12, 2025 | A · derivative | 62,000 | $0.70 | $43,400 | 62,000 | No | Form 4 |
| Gilead Sciences, Inc. | Jun 5, 2025 | Jun 6, 2025 | P · derivative | 13,335,000 | not reported | Purchase not reported | 23,310,266 | No | Form 4 |
| Gilead Sciences, Inc. | Jun 5, 2025 | Jun 6, 2025 | P · derivative | 13,335,000 | $0.75 | Purchase +$10,001,250 | 13,335,000 | No | Form 4 |
| Gilead Sciences, Inc. | Jun 5, 2025 | Jun 6, 2025 | P · derivative | 13,335,000 | $0.75 | Purchase +$10,001,250 | 13,335,000 | No | Form 4 |
| Gilead Sciences, Inc. | Jun 5, 2025 | Jun 6, 2025 | P · derivative | 13,335,000 | $0.75 | Purchase +$10,001,250 | 13,335,000 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Apr 15, 2025 | Apr 16, 2025 | A · derivative | 75,000 | $0.71 | $53,250 | 75,000 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Apr 15, 2025 | Apr 16, 2025 | A · derivative | 190,000 | $0.71 | $134,900 | 190,000 | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Jan 2, 2025 | Jan 3, 2025 | S | 1,803 | $0.98 | Sale −$1,767 | 3,197 | Yes | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Jan 2, 2025 | Jan 3, 2025 | S | 6,954 | $0.98 | Sale −$6,815 | 12,421 | Yes | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Jan 1, 2025 | Jan 3, 2025 | M | 5,000 | not reported | not reported | 5,000 | Yes | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Jan 1, 2025 | Jan 3, 2025 | M · derivative | 5,000 | $0.00 | $0 | 15,000 | Yes | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Jan 1, 2025 | Jan 3, 2025 | A · derivative | 60,000 | $0.96 | $57,600 | 60,000 | Yes | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Jan 1, 2025 | Jan 3, 2025 | M | 16,625 | not reported | not reported | 16,625 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Jan 1, 2025 | Jan 3, 2025 | M · derivative | 16,625 | $0.00 | $0 | 49,875 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Jan 1, 2025 | Jan 3, 2025 | A · derivative | 200,000 | $0.96 | $192,000 | 200,000 | No | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Jan 1, 2025 | Jan 3, 2025 | M | 19,375 | not reported | not reported | 19,375 | Yes | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Jan 1, 2025 | Jan 3, 2025 | M · derivative | 19,375 | $0.00 | $0 | 58,125 | Yes | Form 4 |
| Frankenfield Christopher JamesChief Financial Officer | Jan 1, 2025 | Jan 3, 2025 | A · derivative | 251,000 | $0.96 | $240,960 | 251,000 | Yes | Form 4 |
| Gilead Sciences, Inc. | Dec 18, 2024 | Dec 19, 2024 | P | 1,759,978 | $1.04 | Purchase +$1,830,377 | 9,105,451 | No | Form 4 |
| Gilead Sciences, Inc. | Dec 18, 2024 | Dec 19, 2024 | P · derivative | 6,092,816 | $1.04 | Purchase +$6,336,529 | 9,975,266 | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Oct 1, 2024 | Oct 2, 2024 | A · derivative | 26,000 | $0.75 | $19,500 | 26,000 | No | Form 4 |
| Frankenfield Christopher JamesChief Operating Officer | Aug 3, 2024 | Aug 6, 2024 | A · derivative | 52,000 | $0.90 | $46,800 | 52,000 | No | Form 4 |
| Curran Daniel J. | Jun 14, 2024 | Jun 17, 2024 | A · derivative | 25,000 | $1.02 | $25,500 | 25,000 | No | Form 4 |
| Clancy Paul J | Jun 14, 2024 | Jun 17, 2024 | A · derivative | 25,000 | $1.02 | $25,500 | 25,000 | No | Form 4 |
| Rossi Christina | Jun 14, 2024 | Jun 17, 2024 | A · derivative | 25,000 | $1.02 | $25,500 | 25,000 | No | Form 4 |
| Ross Robert W. | Jun 14, 2024 | Jun 17, 2024 | A · derivative | 25,000 | $1.02 | $25,500 | 25,000 | No | Form 4 |
| Bonstein Sara | Jun 14, 2024 | Jun 17, 2024 | A · derivative | 25,000 | $1.02 | $25,500 | 25,000 | No | Form 4 |
| Xu Yuan | Jun 14, 2024 | Jun 17, 2024 | A · derivative | 25,000 | $1.02 | $25,500 | 25,000 | No | Form 4 |
| Brennan Aoife | Jun 13, 2024 | Jun 17, 2024 | A · derivative | 50,000 | $1.05 | $52,500 | 50,000 | No | Form 4 |
| Shannon James Samuel | Jun 13, 2024 | Jun 17, 2024 | A · derivative | 50,000 | $1.05 | $52,500 | 50,000 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | May 1, 2024 | May 3, 2024 | A · derivative | 474,000 | $1.08 | $511,920 | 474,000 | No | Form 4 |
| Frankenfield Christopher JamesCHIEF OPERATING OFFICER | May 1, 2024 | May 3, 2024 | A · derivative | 208,000 | $1.08 | $224,640 | 208,000 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | May 1, 2024 | May 3, 2024 | A · derivative | 59,333 | $1.08 | $64,080 | 59,333 | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | May 1, 2024 | May 3, 2024 | A · derivative | 20,000 | $1.08 | $21,600 | 20,000 | No | Form 4 |
| Gilead Sciences, Inc. | Apr 2, 2024 | Apr 3, 2024 | P | 485,250 | $0.76 | Purchase +$368,790 | 7,345,473 | No | Form 4 |
| Gilead Sciences, Inc. | Apr 2, 2024 | Apr 3, 2024 | P · derivative | 3,882,450 | $0.76 | Purchase +$2,950,662 | 3,882,450 | No | Form 4 |
| Atlas Venture Fund XI, L.P. | Feb 8, 2024 | Feb 9, 2024 | S | 733 | $0.64 | Sale −$469 | 2,019,563 | No | Form 4 |
| Atlas Venture Fund XI, L.P. | Feb 8, 2024 | Feb 9, 2024 | S | 267 | $0.64 | Sale −$171 | 734,546 | No | Form 4 |
| Atlas Venture Associates Opportunity I, L.P. | Jan 12, 2024 | Jan 16, 2024 | S | 1,540 | $0.83 | Sale −$1,278 | 2,020,296 | No | Form 4 |
| Atlas Venture Associates Opportunity I, L.P. | Jan 12, 2024 | Jan 16, 2024 | S | 560 | $0.83 | Sale −$465 | 734,813 | No | Form 4 |
| Atlas Venture Associates Opportunity I, L.P. | Jan 11, 2024 | Jan 16, 2024 | S | 1,566 | $0.87 | Sale −$1,362 | 2,021,836 | No | Form 4 |
| Atlas Venture Associates Opportunity I, L.P. | Jan 11, 2024 | Jan 16, 2024 | S | 569 | $0.87 | Sale −$495 | 735,373 | No | Form 4 |
| Russo RenePRESIDENT AND CEO | Jan 1, 2024 | Jan 3, 2024 | A · derivative | 177,000 | $0.00 | $0 | 177,000 | No | Form 4 |
| Brennan Kevin M.SVP, FINANCE AND ACCOUNTING | Jan 1, 2024 | Jan 3, 2024 | A · derivative | 20,000 | $0.00 | $0 | 20,000 | No | Form 4 |
| Luptakova KatarinaCHIEF MEDICAL OFFICER | Jan 1, 2024 | Jan 3, 2024 | A · derivative | 66,500 | $0.00 | $0 | 66,500 | No | Form 4 |
| Frankenfield Christopher JamesCHIEF OPERATING OFFICER | Jan 1, 2024 | Jan 3, 2024 | A · derivative | 77,500 | $0.00 | $0 | 77,500 | No | Form 4 |